Xtandi

Pharma

Astellas CEO resists 'rescue BD' as Xtandi patent cliff nears

With Xtandi set to lose U.S. patent protection next year, Astellas’ CEO fielded questions this week about his company’s BD strategy ahead of the loss.

Angus Liu Jan 15, 2026 10:42am

Lilly-Innovent, Dizal, bispecific ADC—Fierce Pharma Asia

Jul 10, 2025 5:20pm

Pfizer, Astellas' Xtandi combo extends life in early prostate cancer

Jul 10, 2025 11:52am

FDA approves use of Bayer's Nubeqa in all patients with mCSPC

Jun 4, 2025 11:38am

FDA advisors unanimously reject Pfizer's Talzenna expansion bid

May 22, 2025 10:20am

Pfizer details survival win in bid for broad prostate cancer nod

Feb 13, 2025 10:00am